GLP1R and type 2 diabetes mellitus: Novel therapeutic guidelines for type 2 diabetes recommend the association of prandial GLP-1 receptor agonists to basal insulin; benefits of such pharmacologic combinations bring together the predominant effect of basal insulin on fasting glycemia and the effect of prandial GLP-1 receptor agonists on postprandial glycemia, based on their ability to inhibit gastric emptying [86, 87].